5-(3-fluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(3-fluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid
• 英文别名: 5-(3-fluorophenyl)-5-methyl-4-oxofuran-2-carboxylic acid
• 化学式: C₁₂H₉FO₄
• 分子量: 236.199
• InChiKey: BLOJHYLVLSDXLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3'-氟苯乙酮 在 甲醇 、 lithium hydroxide 、 正丁基锂 、 mercury(II) perchlorate 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 为溶剂， 生成 5-(3-fluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid
  参考文献：
  名称：

  Analogues of Acifran:  Agonists of the High and Low Affinity Niacin Receptors, GPR109a and GPR109b

  摘要：

  Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.

  DOI：

  10.1021/jm070022x

文献信息

• 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
  申请人：Jung Jae-Kyu

  公开号：US20070093545A1

  公开（公告）日：2007-04-26

  System for selecting a colour shade comprising a very small number of colour display cards with mixed shades of two or more colours. The system comprises means for selecting one shade among mixed shades, means for presenting the selected mixed shade as well as means for specifying the selected mixed shade for making paint in the desired colour tone.

  选择颜色色调的系统，包括非常少量的混合两种或更多颜色的颜色显示卡。该系统包括选择混合色调中的一种色调的手段，呈现所选的混合色调的手段，以及指定所选的混合色调以制作所需颜色色调的油漆的手段。
• 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
  申请人：Jung Jae-Kyu

  公开号：US20070161701A1

  公开（公告）日：2007-07-12

  System for selecting a colour shade comprising a very small number of colour display cards with mixed shades of two or more colours. The system comprises means for selecting one shade among mixed shades, means for presenting the selected mixed shade as well as means for specifying the selected mixed shade for making paint in the desired colour tone.

  一种用于选择颜色色调的系统，包括极少数量的混合两种或多种颜色的颜色展示卡。该系统包括选择混合色调中的一种色调的手段，呈现所选混合色调的手段以及指定所选混合色调以制作所需颜色调的油漆的手段。
• 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP1701947A2

  公开（公告）日：2006-09-20
• US7803837B2
  申请人：——

  公开号：US7803837B2

  公开（公告）日：2010-09-28
• [EN] 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE 4-OXO-4,5-DIHYDROFURANE-2 ET METHODES POUR TRAITER DES TROUBLES DU METABOLISME
  申请人：ARENA PHARM INC

  公开号：WO2005051937A2

  公开（公告）日：2005-06-09

  The present invention relates to certain 4-oxo-4,5-dihydro-furan-2-carboxylic acid and ester derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X, and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, and the like.